

主な研究課題・発表代表論文

臨床薬理学講座 Clinical Pharmacology

研究領域 臨床薬理学

教授 北原 隆志 Takashi Kitahara

Web ページ : <https://ds.cc.yamaguchi-u.ac.jp/~yakuzai/index.html>

主な研究課題

- ・微量分析および薬物動態解析を用いた薬物療法最適化に関する研究
- ・薬剤性臓器障害マーカーの探索および臨床への応用研究
- ・種々のリアルワールドデータを用いた医薬品関連有害事象評価法の構築と臨床への応用
- ・合理的な薬物療法を提供するためのエビデンス創出に関する研究
- ・薬剤師業務の科学的な有用性評価に基づく職能評価に関する研究

発表代表論文

1. N. Okada, T. Kitahara et al. Effect of pre-treatment of EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database. *Int J Clin Pharmacol Ther.* 2023 in press.
2. N. Okada, T. Kitahara et al. Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-Methicillin-Resistant Staphylococcus aureus Agents: Analysis Using Food and Drug Administration Adverse Event Reporting System. *Open Forum Infectious Diseases.* 10, ofad414, 2023
3. Y. Kouki, N. Okada, T. Kitahara et al. Disproportionality Analysis on Hypothyroidism with Roxadustat using the Japanese Adverse Drug Event Database. *J Clin Pharmacol.* 63(10):1141-1146, 2023
4. T. Oka, N. Okada, T. Kitahara et al. A low Prognostic Nutritional Index is associated with increased remote infections within 30 days of colorectal surgery: A retrospective cohort study. *Am J Infect Control,* 63, 1141-1146, 2023
5. C. Hino, T. Kitahara et al. Peripheral Parenteral Nutrition Solutions and Bed Bath Towels as Risk Factors for Nosocomial Peripheral Venous Catheter-related Bloodstream Infection by Bacillus cereus. *Int J Med Sci.* 20, 566-571, 2023
6. N. Okada, T. Kitahara et al. Clinical impact of anti-polyethylene glycol (PEG) antibody in haematological patients administered PEGylated-granulocyte colony-stimulating factor. *Clin Pharmacol Drug Dev.* 12, 826-831, 2023
7. A. Saisyo, T. Kitahara et al. Pharmacoeconomic study of biologics for psoriasis treatment based on real-world drug survival. *Dermatol Ther.* 5: e15375, 2022

8. N. Okada et al. Clinical impact of a pharmacist-driven prospective audit with intervention and feedback on the treatment of patients with bloodstream infection. *Antibiotics*.11: 1144.2. 2022
9. N. Okada et al. Hospital outbreak of extended-spectrum beta-lactamase-producing *Escherichia coli* potentially caused by toilet and bath chair use. *Infect Prev Pract*. 4: 100239. 2022
10. N. Okada et al. First reported case of *Lachnoanaerobaculum gingivalis* bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy. *Anaerobe*. 76: 102610. 2022
11. M.Maeda, T. Kitahara et al, Bibliometric analysis of pharmacist's research on antimicrobial stewardship in Japan: an interrupted time series analysis on the implementation of the certification system for infection control pharmacists. *J Pharm Health Care Sci*. 7: 38, 2021
12. N. Okada et al. Impact of area under the concentration-time curve on the prevalence of vancomycin-induced nephrotoxicity in combination with tazobactam/piperacillin or cefepime: A single-institution retrospective study. *Clin Ther*. 43: 1910-1920.e3. 2021
13. N. Okada et al. Assessment of adherence to post-exposure prophylaxis with oseltamivir in healthcare workers: A retrospective questionnaire-based study. *Biol Pharm Bull*. 44: 869-874. 2021
14. M. Ozaki, T. Kitahara et al. Evaluation of the antiemetic effect of premedication optimized by pharmaceutical support in cisplatin regimens. *Biol Pharm Bull*. 43: 1735-1741. 2020
15. N. Okada et al. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. *Sci Rep*. 10: 13773. 2020
16. N. Okada et al. Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study. *European Journal of Clinical Pharmacology*. 5: 1695-1704, 2019
17. N. Okada et al. Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database. *Cancer Medicine*, 8: 174-181, 2019
18. N. Okada et al. Relationship between immune-related adverse events and clinical efficacy in melanoma patients treated with nivolumab: a multicenter retrospective study. *Clin Ther*. 41: 59-67, 2019